ES2389376T3 - Composición farmacéutica que comprende ester de temozolomida - Google Patents

Composición farmacéutica que comprende ester de temozolomida Download PDF

Info

Publication number
ES2389376T3
ES2389376T3 ES05785075T ES05785075T ES2389376T3 ES 2389376 T3 ES2389376 T3 ES 2389376T3 ES 05785075 T ES05785075 T ES 05785075T ES 05785075 T ES05785075 T ES 05785075T ES 2389376 T3 ES2389376 T3 ES 2389376T3
Authority
ES
Spain
Prior art keywords
acid
carboxylate
tmz
pharmaceutical composition
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05785075T
Other languages
English (en)
Spanish (es)
Inventor
Yongfeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Tasly Group Co Ltd
Original Assignee
Tianjin Tasly Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Tasly Group Co Ltd filed Critical Tianjin Tasly Group Co Ltd
Application granted granted Critical
Publication of ES2389376T3 publication Critical patent/ES2389376T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES05785075T 2004-09-22 2005-09-15 Composición farmacéutica que comprende ester de temozolomida Expired - Lifetime ES2389376T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410072056 2004-09-22
CNA2004100720564A CN1752088A (zh) 2004-09-22 2004-09-22 含有替莫唑胺酯的药用组合物
PCT/CN2005/001477 WO2006032190A1 (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester

Publications (1)

Publication Number Publication Date
ES2389376T3 true ES2389376T3 (es) 2012-10-25

Family

ID=36089840

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05785075T Expired - Lifetime ES2389376T3 (es) 2004-09-22 2005-09-15 Composición farmacéutica que comprende ester de temozolomida

Country Status (20)

Country Link
US (1) US7579336B2 (enExample)
EP (1) EP1798234B1 (enExample)
JP (2) JP5620046B2 (enExample)
KR (1) KR101065984B1 (enExample)
CN (1) CN1752088A (enExample)
AR (1) AR050947A1 (enExample)
AU (1) AU2005287799B2 (enExample)
BR (1) BRPI0515555A (enExample)
CA (1) CA2580910C (enExample)
DK (1) DK1798234T3 (enExample)
ES (1) ES2389376T3 (enExample)
IL (1) IL182027A (enExample)
MX (1) MX2007003366A (enExample)
MY (1) MY153713A (enExample)
NZ (1) NZ554609A (enExample)
PL (1) PL1798234T3 (enExample)
RU (1) RU2393160C2 (enExample)
UA (1) UA89795C2 (enExample)
WO (1) WO2006032190A1 (enExample)
ZA (1) ZA200702801B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1727340B (zh) * 2004-07-29 2011-05-18 天津帝士力投资控股集团有限公司 一种替莫唑胺-8-羧酸酯及其组合物
EP1808173A1 (en) * 2006-01-12 2007-07-18 Matthias Dormeyer Use of CNS penetrating anticancer compounds for the treatment of protozan diseases
US8558511B2 (en) * 2009-04-07 2013-10-15 Battelle Memorial Institute Method and apparatus for smart battery charging including a plurality of controllers each monitoring input variables
KR20140087846A (ko) * 2012-12-31 2014-07-09 주식회사 삼양바이오팜 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
RU2527258C1 (ru) * 2013-02-19 2014-08-27 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ
US10709715B2 (en) * 2017-12-03 2020-07-14 Cipla Limited Method of treating hypertension
CN113271939B (zh) * 2018-08-09 2025-03-07 伊利诺伊大学董事会 咪唑四嗪化合物
CN114014862A (zh) * 2021-06-28 2022-02-08 烟台大学 一种治疗脑胶质瘤的新化合物及其制备和应用
CN116947765B (zh) * 2022-06-23 2025-10-10 北京新源医疗有限责任公司 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8616125D0 (en) * 1986-07-02 1986-08-06 May & Baker Ltd Compositions of matter
UA29466C2 (uk) * 1993-01-14 2000-11-15 Канзер Рісерч Кампейн Технолоджі, Лтд Фармацевтична композиція з антипухлинною активністю
CN1244583C (zh) * 2002-09-29 2006-03-08 天津天士力集团有限公司 替莫唑胺－8－羧酸脂和－8－酰胺衍生物，它们的合成方法以及它们在制备抗癌制剂中的应用
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途

Also Published As

Publication number Publication date
US20080044457A1 (en) 2008-02-21
MX2007003366A (es) 2008-03-05
RU2393160C2 (ru) 2010-06-27
AU2005287799A1 (en) 2006-03-30
BRPI0515555A (pt) 2008-07-29
JP2008513523A (ja) 2008-05-01
EP1798234A4 (en) 2009-04-29
RU2007114948A (ru) 2008-10-27
CA2580910A1 (en) 2006-03-30
JP2013028630A (ja) 2013-02-07
IL182027A (en) 2014-05-28
JP5620046B2 (ja) 2014-11-05
PL1798234T3 (pl) 2012-11-30
EP1798234B1 (en) 2012-06-13
WO2006032190A1 (en) 2006-03-30
MY153713A (en) 2015-03-13
KR101065984B1 (ko) 2011-09-19
CA2580910C (en) 2011-10-25
IL182027A0 (en) 2007-07-24
UA89795C2 (ru) 2010-03-10
AU2005287799B2 (en) 2009-03-26
HK1100440A1 (en) 2007-09-21
CN1752088A (zh) 2006-03-29
US7579336B2 (en) 2009-08-25
ZA200702801B (en) 2008-08-27
KR20070062569A (ko) 2007-06-15
DK1798234T3 (da) 2012-08-27
AR050947A1 (es) 2006-12-06
NZ554609A (en) 2010-06-25
EP1798234A1 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
ES2978534T3 (es) Análogos de éter de fosfolípidos como vehículos de fármacos contra el cáncer
ES2971077T3 (es) Formulación que comprende un inhibidor mek
ES2525866T3 (es) 8-alquil-7-oxo-7,8-dihidropirido [2,3-d]pirimidina-6-carbonitrilos sustituidos en 2 y usos de los mismos
ES2659541T3 (es) Compuestos y composiciones novedosas para direccionar hacia células madre del cáncer
ES2906785T3 (es) Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones
CN117157292A (zh) Kras g12d抑制剂和其用途
ES2870614T3 (es) Hemihidrato de la base libre de la N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida, métodos para su fabricación y sus usos
JP2013028630A (ja) テモゾロマイドエステルよりなる医薬組成物
KR20170137916A (ko) 우라실 화합물의 신규 결정
EP3279201B1 (en) Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
WO2022121670A1 (zh) Tolebrutinib的晶型及其制备方法和用途
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
EP3920911A1 (en) Topical phosphoinositide 3-kinase inhibitors
ES2959891T3 (es) Producción de trans-[tetraclorobis(1H-indazol)rutenato (III)] y composiciones del mismo
ES2343204T3 (es) Formas cristalinas nuevas de hidrocloruro de irinotecan.
WO2006024238A1 (en) The pharmaceutical composition containing temozolomide-8-carboxylic esters and the use of the temozolomide-8-carboxylic esters for manufacture of the anti-tumour medicine
CN111518157B (zh) 一种雷公藤甲素衍生物及其制备方法和应用
ES2369365T3 (es) Composiciones formadoras de partículas que contienen pirrolocarbazoles fusionados.
KR20200129705A (ko) 무정형의 pi3k 저해제 및 이를 포함하는 약학적 조성물
HK1100440B (en) Pharmaceutical composition comprising temozolomide ester
WO2022256550A1 (en) Crystalline forms of an adenosine a2b receptor antagonist
ES3039287T3 (en) Crystal of pyrazolo[3,4-d]pyrimidine
CN108586535A (zh) 含喜树碱结构的磷脂类似物、制备方法及用途
CN119235877A (zh) 一种钌(iii)酸盐的组合物及其应用
CN111138282A (zh) 绿原酸l-精氨酸盐及其用途